摘要
目的通过对高血压前期的降压药物干预,观察血尿酸(UA)、C-反应蛋白(CRP)的变化,探索血尿酸、C-反应蛋白与高血压前期的相关性及对高血压前期降压药物干预的必要性。方法入选2007年至2009年我院门诊体检符合高血压前期人群共238例,随机分成A组(安慰剂组)114例,B组(降压药物干预组)124例,对A、B组均监测血压3年,其中A组给予安慰剂,对B组前1年半予厄贝沙坦降压治疗,后1年半也给予安慰剂,A、B组同时观察血压、血尿酸、C-反应蛋白的变化。结果 A组88例发展为高血压,血尿酸、C-反应蛋白进行性升高,B组前1年半仅有11例发展为高血压,血尿酸、C-反应蛋白与治疗前比较无明显升高,后1年半B组共有93例发展为高血压,血尿酸、C-反应蛋白较前也明显升高,与A组比较无统计差异。结论血尿酸、C-反应蛋白与血压独立相关,对高血压前期人群应尽早予以降压药物干预,以降低高血压的发生率及控制心脑血管病的危险因素,从而减少心脑血管疾病的发生、发展。
Objective To compare the serum level of uric acid and C-reactive protein in pre-hypertension patients with or without the intervention of antihypertensive drug to investigate the necessity to antihypertensive drug therapy in patients with pre-hypertension. Methods 238 patients who were diagnosed as pre-hypertension in the OPD from 2007 to 2009 were chosen and divided into group A（n=114） and group B（n=124）. Patients in group A were treated with placebo, and those in group B were treated with Irbesartan in first 18 months, followed by treating with placebo in next 18 months. Blood preesure, serum uric acid and C-reactive protein were detected in both groups. Results 88 patients in group A developed into hypertension, and the serum level of uric acid and C-reactive protein progressive increased. Meanwhile only 11 cases in group B developed into hypertension in the first 18 months, and serum level of uric acid and C-reactive protein in these patients did not significant increased. In the next 18 months, 93 patients in group B developed into hypertension, and the serum lelvel of uric acid and C-reactive protein in these patients significantly increased. Conclusion Serum uric acid and C-reactive protein, were the independent risk factors for hypertension. The pre-hypertension patients should be treated by antihypertensive drug as early as possible.
出处
《中国医药指南》
2013年第16期55-56,共2页
Guide of China Medicine
关键词
高血压前期
血尿酸
C-反应蛋白
降压药物
Prehypertension
Serum uric acid
C-reactive protein
Antihypertensive drug
